



Published in final edited form as:

J Cardiovasc Electrophysiol. 2021 October ; 32(10): 2854–2864. doi:10.1111/jce.15116.

Recent advances in gene therapy for atrial fibrillation

Shin Yoo, PhD,

Gail Elizabeth Geist, DVM,

Anna Pfenniger, MD, PhD,

Markus Rottmann, PhD,

Rishi Arora, MD

Feinberg Cardiovascular and Renal Research Institute, Northwestern University-Feinberg School of Medicine, Chicago, Illinois, USA

Abstract

Atrial fibrillation (AF) is the most common heart rhythm disorder in adults and a major cause of stroke. Unfortunately, current treatments for AF are suboptimal as they are not targeting the molecular mechanisms underlying AF. In this regard, gene therapy is emerging as a promising approach for mechanism-based treatment of AF. In this review, we summarize recent advances and challenges in gene therapy for this important cardiovascular disease.

Keywords

atrial fibrillation; gene therapy

1 | INTRODUCTION

Atrial fibrillation (AF) is the most common heart rhythm disorder, with an estimated prevalence of 12.1 million individuals in the United States alone by 2030.¹ AF is a cause of significant morbidity and mortality, and because the incidence of AF increases with age, it is fast becoming an epidemic worldwide.^{2,3} Despite its clinical importance, AF is a difficult condition to treat. Current therapies for AF include antiarrhythmic drugs and ablation to electrically isolate the pulmonary veins.⁴ Ablation is mostly effective for paroxysmal AF, with more limited efficacy in persistent AF, and is also associated with complications. Antiarrhythmic drugs have limited long-term efficacy and can be associated with significant adverse effects, including proarrhythmia and effects on the nervous system.⁵

Given these challenges, researchers are actively investigating new treatments, including gene-based approaches to directly and specifically target the signaling pathways in the atrial myocardium that underlie the creation of electrical and structural remodeling in AF. In the preclinical stage, promising results having been obtained in animal models that parallel the

Correspondence: Shin Yoo, PhD, Northwestern University-Feinberg School of Medicine, 303 East Chicago, Tarry 12-755, Chicago, IL 60611, USA. shinyoo@northwestern.edu; Rishi Arora, MD, Northwestern University-Feinberg School of Medicine, 251 East Huron, Feinberg 8-503, Chicago, IL 60611, USA. r-arora@northwestern.edu.

Disclosures: Rishi Arora: Ownership interest, Rhythm Therapeutics, Inc. Other authors: No disclosures.

electrical and structural remodeling seen in humans. While gene therapy holds great hope to produce a highly effective and personalized treatment for a diverse range of cardiac disorders, safe and successful clinical translation is in a nascent phase and therapies must be designed with careful attention to an ever-expanding body of knowledge.

In this review, we will begin by discussing the current state and advances in gene transfer, with a focus on the gene therapy vectors and methods for delivery of these vectors to the atrium. We will then examine molecular targets based upon AF mechanisms. Further, we will discuss the potential of novel AF mapping strategies to better target gene therapy delivery.

2 | OVERALL STRATEGIES OF MYOCARDIAL GENE TRANSFER

The overarching concept of cardiac gene therapy is simple: replace or remove a disease-causing gene at the level of the myocardium, thereby eliminating a fundamental incipient for a given condition. In practice, there is an array of selection criteria and obstacles to consider. For any gene therapy to be successful, the gene(s) of interest must not only be delivered but also expressed at adequate concentrations in the target tissue bed. The tools used to accomplish this gene transfer are known as vectors. The ideal vector allows tissue selectivity, low immunogenicity, adequate packaging capacity, and a durable level of gene expression. To date, current vector options incorporate some, but not all of these attributes. Vectors can be described in two broad categories: viral (gene transduction) and nonviral (transfection). Following selection, the vector of choice may be delivered to the myocardium through a variety of techniques over a spectrum of invasiveness and specificity. There is no single optimal combination of the above factors; rather, it is necessary to understand the appropriate applications and limitations of each.

3 | GENE THERAPY VECTORS

3.1 | Nonviral vectors

3.1.1 | Naked plasmid DNA—While primarily used for in vitro gene transfer, plasmid DNA remains the most accessible tool for gene transfer in vivo. Plasmids are circular DNA constructs that can be customized with a versatile combination of transgenes and regulatory elements. Compared to other vectors, naked plasmids can hold significantly larger quantities of genetic information.^{6,7} Plasmids are also easy to produce, with adequate infrastructure for clinical-grade plasmids already in place.⁸ Naked plasmid DNA is nonimmunogenic; while an immune response can be mounted against the foreign transgene product, there is no immune response generated against the plasmid itself.⁹ This lack of vector-directed immune response enhances safety and allows for potential repeated administration of plasmid-based gene therapies.

However, naked plasmid alone transduces cells at therapeutically irrelevant levels,¹⁰ and enhancement with transfection reagents is only marginally effective for gene uptake.^{11,12} Overcoming this limitation requires select methods of administration, which will be discussed later in this review. In addition, plasmid DNA is not integrated in the genome, leading to a limited duration of expression. Prolongation of this expression is under

investigation through numerous studies on select promoters. Our group has previously demonstrated expression of a dominant-negative transforming growth factor beta (TGF- β) II receptor under the control of a long-acting polyubiquitin C (UBC) promoter for at least 3–4 weeks in a canine heart failure model of AF.¹³ Similarly, intermediate term gene expression has been demonstrated by others in murine myocardium, bone, skeletal muscle, and lung.^{14–18} While long term data has yet to be reported, the option of repeated rounds of plasmid gene therapy could compensate for loss of transgene expression over time.

3.1.2 | Nanoparticles—Another choice of nonviral vector for myocardial gene transfer is the usage of nanoscale liposomes. Lipid-based nanoparticles offer biocompatibility, good cellular uptake, and can be deployed with targeting ligands to enhance tissue specificity. The liposomal delivery mechanism for small molecule drugs is already in clinical use as a chemotherapeutic vehicle, and lipid-based nanoparticles containing a genetic construct have a demonstrated ability for transducing cardiac cells.^{19,20} However, off-target tissue effects may still be encountered when nanoparticles are administered via systemic circulation, and charged lipid particles are subject to rapid clearance by the reticuloendothelial system. Future advances in liposomal stability, distribution, and release offer potentially exciting avenues for cardiac gene delivery.^{20,21}

3.1.3 | Another nonviral vector, modified-messenger RNA (mRNA) (modRNA)

—In the early 1990s, mRNA was successfully delivered to brain and skeletal muscle.^{22,23} However, the use of mRNA as gene delivery vector to mammalian tissue did not evolve since then. This is mostly due to mRNA induced innate immune response via stimulation of Toll-like receptors.²⁴ Furthermore, mRNA is likely cleaved by RNase *in vivo*.²⁴ In 2005, Dr. Katalin Karikó, who contributed to recent development of COVID-19 mRNA vaccine, demonstrated that modifying mRNA's secondary structure by replacement of uridine with pseudouridine prevented innate immune system recognition and RNase degradation.²⁵

Compared to DNA vectors, modRNA has advantages and disadvantages as a gene delivery tool. One advantage is that mRNA does not require localization of the nucleus or transcription process. modRNA gene delivery has minimal risk of integration into the host genome.²⁶ modRNA has been shown to be highly efficient with robust transient expression with no sign of innate immune response.²⁷ modRNA is translated within minutes and lasts up to 10 days *in vivo*.²⁸

The use of modRNA in heart is mainly for myocardial ischemia/reperfusion injury in ventricle because of its transient pharmacokinetic profile.^{29,30} Disadvantages of modRNA are unstable modRNA generation and the need for repeated delivery due to its short expression pattern. To date, modRNA has not been tested in AF treatment yet. If translation efficiency of modRNA is improved, modRNA can be another nonviral vector for AF.

3.2 | Viral vectors

Viral vectors are live, replication-deficient viruses which have been genetically modified to replace the native viral genes with therapeutic transgenes. Any cell that the vector infects integrates the transgene payload to produce or inhibit a genetic product. Compared to nonviral plasmids which must be delivered directly to the tissue of interest, viral vectors

have the theoretical advantage of minimally invasive delivery via the bloodstream. There are three main types of viral vectors used today in gene therapy, though the adeno-associated virus (AAV) is currently best suited for cardiac gene therapy.

3.2.1 | Adeno-associated virus—First isolated as an unrelated contaminant in adenovirus samples, AAV is a non-enveloped, nonintegrating single-stranded DNA parvovirus. AAV emerged as a focus of gene therapy vector development due to low immunogenicity, potential for long duration of expression, and a robust safety profile.^{31–33} AAV is capable of durable, possibly life-long transgene expression in vivo: no upper limit to duration of expression has been determined, with numerous studies showing transgene expression years after a single administration. Notably, AAV alone is incapable of productive replication and requires coinfection with a helper virus, usually adenovirus or herpesvirus. The lack of self-replication machinery increases the safety of AAV, but also limits the size of its genome to about 4.7 kb.

The primary AAV serotypes are AAV 1–9. While more serotypes and variants have been characterized and silent infection is highly prevalent in humans, no associated pathogenicity has been identified.³⁴ Each serotype has a distinct capsid protein sequence correlating to variable tissue tropism, with AAV serotypes 1, 6, 8, and 9 exhibiting the highest cardiac tropism.^{35,36} By engineering the makeup of the viral capsid proteins, it is possible to generate novel, chimeric AAVs with improved transduction efficiency and tropism in rodent models.^{37–39} Tissue specificity can also be achieved with the use of site specific promoters to drive transgene expression only in the atria.⁴⁰ While transduction efficiency is often more limited in scale-up from rodent to large animal models, these emerging strategies are accompanied with recent Food and Drug Administration-approval for noncardiac gene therapies and a number of clinical trials utilizing an AAV vector.^{41–43}

The primary disadvantage of AAV vectors is limited transgene size. When including a cardiac-specific promoter, many transgenes exceed the maximal size for an AAV construct. Additionally, a clinical effect may be delayed as gene expression requires conversion of the single-stranded viral genome to the double stranded host genome.⁴⁴ AAV-mediated gene therapy is further hindered by the potential preexisting neutralizing immune response generated against AAV capsid proteins, described in further detail in a following section.

3.2.2 | Adenovirus (Ad)—The wild-type Ad is a nonenveloped, nonintegrating double stranded DNA virus, ubiquitous in the environment and one of the causative agents of the common cold. Ad vectors are simple to produce, transduce both dividing and nondividing cells with high efficiency, and have a packaging capacity for moderate sized genes.⁴⁵ However, in the heart, gene expression after Ad vector transduction is robust but transient and Ads can trigger a strong innate immune response and toxicity due to viral gene products.⁴⁶ The use of Ads was heavily scrutinized in 1999 after the death of a patient with ornithine transcarbamylase deficiency due to a massive immune response following injection of Ad vector.⁴⁷ Recombinant modifications have given rise to first, second, and third-generation Ad vectors, with key immunogenic components deleted. These advanced vectors show promise for evading the host immune response and producing a prolonged gene expression, but are more difficult to produce.⁴⁸

3.2.3 | Lentivirus (LV)—Lentiviral vectors are enveloped, integrating, single-stranded RNA retroviruses.⁴² In gene therapy, LV vectors are usually derived from the HIV-1 virion, modified to be replication-defective to safeguard against off-target continued infection.^{49,50} Retroviral vectors typically require active cellular division to integrate and express a transgene, but the machinery of HIV conveys an ability to transduce intact nuclear membranes in post-mitotic cells (such as cardiomyocytes), and accomplishes long-term gene expression with moderate packaging capacities.^{51–53} Despite this attractive profile for efficacy, the LV apparatus of random genome integration with a preference for coding regions poses a clinical safety precedent for oncogenic transformation.^{34,48} While terminally differentiated cardiomyocytes pose a lower mutagenic risk than mitotically active tissues, the safety and efficacy of lentiviral vectors for cardiac use have yet to be demonstrated in clinical trials.

3.2.4 | Immunogenicity of viral vectors—The promise of viral vectors is inseparable from the perennial obstacle of inherent immunogenicity. Viral capsids are targets for the innate and humoral immune responses, and foreign transgene products can trigger the adaptive immune response. Adenoviruses are most notoriously associated with immune provocation, resulting in declining use following adverse events in previous clinical trials.⁵⁴ Though the advent of AAV-mediated gene therapy has alleviated many of the safety concerns associated with the use of viral vectors, AAV infections are silently endemic to many human populations. A geographically variable but significant percentage (20%–60%) of humans are predicted to have preexisting neutralizing antibodies (NAbs) against one or more AAV capsids, rendering AAV-mediated treatments ineffective.^{55,56} Furthermore, in naïve patients, initial exposure to an AAV therapy results in generation of NAbs against the AAV capsid, eliminating the potential for readministration of AAV vector-mediated gene therapy.⁵⁷ A complete understanding of the significance of AAV NAb titers and cross-reactivity between serotypes has yet to be established, posing a challenge for clinical study enrollments. Lentiviral vectors possess an advantageous ability to mostly evade the host immune system, however, the foreign transgene product itself can still incite an immune response and subsequent suppression. These altered proteins, while therapeutic, can present to the adaptive immune system as a potent neo-antigen. In an effort to overcome these sophisticated, protective host defenses, immunomodulation at the time of vector administration is an area of active research.⁵⁸

4 | GENE DELIVERY TO THE ATRIAL MYOCARDIUM

A well-administered vector achieves homogeneous delivery at the affected tissue bed and demonstrates minimal accumulation at off-target sites. Vectors can be administered by a wide variety of techniques, but often with an inverse relationship between simplicity and specificity. Route consideration is imperative for patient safety and gene efficacy, and represents an area under active research in parallel with the vector itself.

4.1 | Intravenous administration (IV)

The least invasive method of administration is intravenous injection of the vector. While IV exposure should offer rapid transit to any well-vascularized target tissue, it is also the least

specific route. Upon entering the intravascular compartment, the vector will be systemically dispersed and the tissue beds will be exposed in accordance with the blood flow to each site. AAV and nanoparticle studies have shown that numerous off-target organs, particularly the liver, are transduced following IV administration. This effect poses a clinically relevant concern for decreased efficacy and increased toxicity. To overcome this biodistribution obstacle, site-directed vector engineering including AAV capsid chimerism and nanoparticle targeting ligands may improve specificity and potency.^{21,38}

4.2 | Cardiac perfusion

The common and well-refined clinical practice of coronary artery catheterization offers intracoronary perfusion as a minimally-invasive modification of IV administration. In this form of delivery, the cardiac vasculature is selectively isolated and perfused with the vector to maximize the potency of a single administration. While the vector still enters the systemic circulation, the cardiac tissues encounter the vector before attenuation by dilution or hepatic uptake. However, this high tissue dose is limited by permeability of the coronary endothelium and rapid blood flow clearance through the coronary circulation. These two factors are thought to have contributed to the negative outcome of the CUPID2 trial (AAV1/SERCA2a coronary injection in patients with heart failure).^{59,60} Vascular permeability enhancers (substance P or thrombin) can be coadministered with a vector to enhance myocardial exposure, although any interference with the coronary arterial tree carries the risk of ischemia and could be unacceptable for patients with preexisting cardiac disease.^{34,61}

Retrograde infusion via coronary sinus injection may provide a myocardium-targeted approach without the ischemic risks or patient selection criteria of intracoronary techniques. Here, controlled infusion of the venous structures in the setting of obstructed outflow increases the capillary pressure gradient and drives the vector material into the tissue beds. Exposure time can be prolonged, as distribution is not dependent on arterial flow and the coronary sinus occlusion can be safely tolerated for an extended duration. Large animal studies have demonstrated efficacy for both drug and gene delivery utilizing this technique.^{62–64} While coronary sinus cannulation is generally safe and commonly practiced in routine procedures, trauma to the delicate cardiac veins and myocardial edema are potential complications and necessitate careful injection pressure regulation.³⁴

4.3 | Epicardial gene painting

Epicardial gene painting combines a vector with a protease and a polymer-forming gel to create a “paintable” gel that can be directly applied to the atrial epicardium.⁶⁵ Once applied, the polymer vehicle solidifies at body temperature and provides a substrate for strong adsorption of the vector to the tissue bed. The protease component of the paint facilitates transmural gene transfer in the thin atrial myocardium.⁶⁶

Gene painting is safe and effective in animal models with no significant impact on atrial structure or function.^{65,67} Though epicardial gene painting can yield homogenous and transmural transduction, the primary drawback is the invasiveness of the surgical procedure required to achieve epicardial access. In addition, structures that are difficult to access via the epicardium (posterior left atrium [PLA] and pulmonary veins) may preclude delivery

to the entire atria, and misapplication of the paint could theoretically result in unintended transmural gene delivery to the ventricle.

4.4 | Direct myocardial injection with or without reversible electroporation

As a simple and well-studied method, direct injection of vector into myocardial tissue has been extensively explored as a route of administration. Through a surgical approach, the vector can be precisely injected and an intense concentration of gene expression can be achieved. However, gene expression is highly localized to within a few millimeters of the injection site. In this way, injection-mediated delivery to a large area of the myocardium is technically challenging and inefficient.⁶⁸

Following direct injection, naked plasmid DNA gene therapy vectors require subsequent electroporation for effective myocardial transfection.^{13,69,70} Electroporation acts by subjecting cells to synchronized electrical pulses, resulting in a transient electrical gradient that alters the structure of cell membranes and forms micropores at the cell surface. These micropores enable diffusion of surrounding plasmid into electroporated cells. The rate of gene uptake in vivo is 15–20 fold higher when electroporation is used versus standard plasmid DNA delivery alone.⁷¹ Of note, application of electroporation pulses could induce ventricular fibrillation if electrical stimulus is delivered during ventricular systole.⁷² The risk increases significantly when performed by nonelectrophysiologists. Thus, synchronization of electrical pulse delivery with an electrocardiogram is highly recommended for the safety of the subjects. Irreversible electroporation is a developing procedure used in clinical cardiac electrophysiology to ablate specific regions of the myocardium.⁷³ Modification of pre-existing irreversible electroporation techniques and equipment to reduce delivered current from an electroporation device could be used to transduce the myocardium with plasmid DNA.

5 | TARGETS FOR GENE THERAPY

Effective gene therapy aims to identify and counteract AF mechanisms originating from or kindled by a genetic element.⁷⁴ Two principal driving mechanisms of AF are focal ectopic firing and reentry. Both of these mechanisms are dependent on electrical and structural remodeling, autonomic nerve remodeling and Ca²⁺-handling abnormalities.⁷⁵ Electrical remodeling is typically characterized by shortening of the atrial action potential duration (APD) through a decrease in the L-type Ca²⁺ current and an increase in the inward-rectifier current (I_{K1}), and the emergence of constitutively active acetylcholine-induced potassium current (I_{KACh}).² Structural remodeling results in left atrial enlargement, atrial fibrosis, and gap junction remodeling, culminating as slow and heterogeneous conduction.⁷⁶ In this review, we will limit ourselves to the current state of mechanistic targets utilizing aforementioned gene therapy vectors.

5.1 | Ion channels

Ion channels have long been a pharmacologic target for rhythm management, so it follows that gene therapy would pursue a similar path. Indeed, transfection of plasmid containing a clarithromycin-responsive variant of KCNE2 (Q9E), encoding the IKr regulatory subunit,

hMiRP, lead to prolongation of the APD by administration of clarithromycin 2 weeks later.⁷⁷ Epicardial gene painting of adenovirus containing a dominant-negative variant of KCNH2-G628S (encoding alpha subunit of IKr) resulted in APD prolongation and reduction of AF burden and inducibility in a porcine model of AF.⁷⁸ Similarly, Soucek et al.⁷⁹ confirmed prolongation of APD with myocardial injection and electroporation of adenoviruses expressing same KCNH2 variant in a canine model of AF. Genetic suppression of TASK-1 (Tandem of P Domains in a Weak Inward Rectifying K⁺ Channel–Related Acid-Sensitive K⁺ Channel-1; K2P3.1) through transfection of AAV containing atrial anti-TASK-1 small interfering RNA (siRNA) lead to reduction of expression of TASK-1 and prolongation of atrial APD and refractoriness.⁸⁰

5.2 | Ca²⁺ handling proteins

Abnormal sarcoplasmic reticulum (SR) Ca²⁺ leak via the ryanodine receptor type 2 (RyR2) has been described in atrial cardiomyocytes from AF patients and in various AF models.^{81,82} This disruption in calcium handling contributes to ectopic atrial activity and is implicated in the progression from paroxysmal to persistent AF. Phosphorylation at the residue site S2814 was shown to promote AF in mouse models, with mice harboring a phospho-resistant RyR2 form (S2814A) exhibiting a reduced susceptibility to AF.^{83,84} This was demonstrated across two different mouse models of atrial arrhythmias: (1) mice lacking the RyR2-stabilizing subunit FKBP12.6, which causes spontaneous Ca²⁺ waves and leads to a higher incidence of spontaneous and pacing-induced AF; and (2) mice exhibiting cardiac overexpression of the transcriptional repressor CREM-Ib C-X (CREM-TG), which leads to atrial myopathy and spontaneous AF that progresses from paroxysmal to persistent. Given these findings, gene therapy integrating a phospho-resistant form of RyR2, such as RyR2-S2814A may be indicated as a clinical target of interest.

Calmodulin (CaM) is an important regulator of RyR2. When bound to Ca²⁺, CaM contributes to inactivation of RyR2. This regulatory property was investigated in a mouse model of catecholaminergic polymorphic ventricular tachycardia (CPVT), a syndrome where shortened refractoriness of RyR2 plays a dominant role.^{85,86} Liu et al.⁸⁷ engineered a form of CaM with slowed Ca²⁺ dissociation (CaM M37Q, or therapeutic T-CaM). They showed that injection of AAV9 T-CaM attenuated diastolic Ca²⁺ waves and prevented ventricular tachycardias in a calsequestrin-associated mouse model of CPVT. It is conceivable that gene therapy with T-CaM in the atria would attenuate the SR Ca²⁺ leak, and may therefore reduce atrial triggers and progression from paroxysmal to persistent AF.

5.3 | Autonomic nerve remodeling

The atria are highly innervated by the autonomic nervous system. Vagal stimulation results in shortening of the atrial effective refractory period (ERP) and increased vulnerability to AF.⁸⁸ Acetylcholine (ACh) released from parasympathetic nerves activates muscarinic type 2 receptors which interact with heterotrimeric G proteins: the G $\alpha_{i/o}$ subunits subsequently inhibit adenylate cyclase protein kinase, and the G $\beta\gamma$ subunit activates I_{KACH}.⁸⁹ Despite the apparent importance of the autonomic nervous system in AF, drug therapy studies using β -blockers and selective I_{KACH} blockers have shown modest success.^{90,91} Donahue et al.⁹² pioneered gene therapy targeting specific components of the G-protein autonomic pathway

in the pig AV node as a rate control strategy for ventricular response in AF. In the study, an adenoviral vector encoding for the G-protein alpha inhibitory subunit 2 ($G\alpha_{i2}$) was delivered in the AV node of pigs, thereby mimicking increased vagal tone. There was a substantial increase in the local expression of $G\alpha_{i2}$ and a slowing of conduction through the AV node. Similarly, Murata et al.⁹³ overexpressed the ras-related small G-protein GEM in ovine AV node and showed slower conduction through AV node and reduction of overall heart rate during AF. Conversely, another approach to AF rate control is the knockdown of the stimulatory G protein α subunit ($G\alpha_s$), which mimics beta-blockade. Lugenvil et al.⁹⁴ found that genetic inhibition of $G\alpha_s$ protein using adenovirus containing siRNA against $G\alpha_s$ in the AV node reduced heart rate by 20% and prevented AF-associated cardiac dysfunction in a porcine model.⁹⁴ Our group also targeted of vagal signaling in the left atrium by inhibiting $G\alpha_i$ and $G\alpha_o$ in canine models.⁹⁵ Here, injection of plasmids encoding the inhibitory peptides of $G\alpha_i$ and $G\alpha_o$ to multiple sites in the PLA lead to attenuation of vagal-induced shortening of ERP and diminished AF inducibility during vagal stimulation.⁹⁵

5.4 | Gap junction remodeling

Connexins (Cxs) are subunit transmembrane proteins that oligomerize to construct a connexon, composed of six Cxs. Gap junctions are formed as the connexons of two neighboring cells dock together, permitting direct cell-cell communication and bidirectional passage of ions and small molecules up to 1 kd.⁹⁶ Reduced expression or abnormal localization of Cx40 and Cx43 are associated with impaired electrical conduction in the atrium and an increased risk of developing AF.^{97,98} Accordingly, gene transfer of both of these connexins using an epicardial painting approach significantly improved expression and localization of the proteins, and was associated with improved conduction and a reduction in arrhythmia burden in a porcine model of AF.⁹⁹ A separate study of Cx43 alone in the same type of model resulted in similar findings, with a marked reduction in the development of persistent AF.¹⁰⁰

5.5 | Structural remodeling

Atrial fibrosis is also a well-known factor in the pathogenesis of AF, and may explain the increasing prevalence of this arrhythmia with age. A central feature of age-related fibrosis is upregulation of TGF- β .¹⁰¹ The PLA has been found to play an important role in the maintenance of AF due to an increase in susceptibility to fibrosis and inhomogeneous conduction.¹³

Our group evaluated the effect of a transgene that interferes with TGF- β signaling on structural remodeling in the PLA. Injection of a minigene expressing a dominant-negative type II TGF- β receptor in the PLA of a canine HF model of AF resulted in decreased fibrosis and reduction in pacing-induced AF in the treated animals.¹³

5.6 | Inflammation/oxidative injury

AF is a multifactorial disease and there is an ample evidence supporting the involvement of inflammation and oxidative injury in the pathophysiology of AF.^{102,103} Inflammatory processes have been shown to affect the electrical and structural properties of the atria.¹⁰⁴ The importance of the NLRP3 (NACHT, LRR, and PYD domains-containing protein 3)

inflammasome in the development of AF was recently established. The activity of NLRP3 inflammasomes is altered not only in patients with AF but also in canine RAP model and in a murine model of spontaneous AF (CREM-TG mice), suggesting a major role for NLRP3 inflammasome in AF pathophysiology in the context of different pathologies. Yao et al.¹⁰⁵ found that pharmacological inhibition by MCC950, an AAV9-mediated shRNA delivery to knockdown NLRP3, or genetic inhibition by NLRP3 knockout prevented the development of AF.

Oxidative injury results from the imbalance between the generation and neutralization of reactive oxygen species (ROS), is a major contributor for AF and a possible therapeutic target.^{106,107} ROS generated in the cardiovascular system are primarily derived from NADPH oxidase (NOX), mitochondrial electron transport chain, xanthine oxidase and uncoupled nitric oxide synthase.^{108,109} Despite considerable evidence that ROS play an important role in the generation of AF, clinical trials using conventional antioxidants for post-operative AF have been unsuccessful,^{110,111} likely because antioxidants do not reach sufficient, localized concentrations to overcome kinetic limitations and allow for scavenging of highly reactive free radical species.¹¹² Our group recently demonstrated a clear causative role of NOX2-generated oxidative injury in the genesis as well as the maintenance of AF. We showed that oxidative injury contributes to electrical remodeling in AF by upregulating a constitutively active form of acetylcholine-dependent K⁺ current ($I_{K_{ACh}}$)—called I_{KH} —by a mechanism involving frequency-dependent activation of protein kinase C epsilon (PKC_ε). Injection and electroporation of plasmids expressing shRNA against NOX2 in the atrium of a canine AF model not only delayed the time to onset of nonsustained AF more than fivefold but also prevented the development of sustained AF for up to 12 weeks.¹¹³

5.7 | Apoptosis

Apoptosis is associated with inflammatory pathways which contribute to electrical and structural remodeling in AF.¹⁰⁴ Downregulation of caspase-3 in canine AF model indicated association of apoptosis with AF via inhibition of calpain, a intracellular Ca²⁺ activated protease.¹¹⁴ Genetic knockdown of caspase-3 by transfer of adenovirus containing siRNA against caspase-3 suppressed or delayed the onset of persistent AF by reduction in apoptosis and prevention of conduction delay in porcine model.¹¹⁵

MicroRNAs are a class of endogenous noncoding small RNAs that are becoming more recognized to play an important role in pathogenesis of AF. Zhang et al.¹¹⁶ examined differential expression of miRNA in ganglionic plexus of a canine AF model and found expression of miR-206 was elevated 10 fold and lentiviral infection of miR-206 resulted in repression of superoxide dismutase-1 (SOD-1).¹¹⁶ Anti-miR-206 infection with lentiviral vector, thus, lead to prolongation of ERP and reduction of AF inducibility.¹¹⁶

6 | GENE DELIVERY IN EXPERIMENTAL AND TRANSLATIONAL STUDIES

6.1 | Gene delivery in small AF animal models

Inducing AF in animal models is challenging due to the use of relatively young animals, size of certain species and the time required for model development. Mouse models have

been helpful for characterizing the contributions of specific genes and signaling pathways to arrhythmogenesis.¹¹⁷ Intravenous gene delivery via tail, jugular, or retro-orbital veins is widely used gene delivery technique in mice because it appears to be not only the least invasive but also effective to administer a vector for myocardial gene delivery.¹¹⁸ Intracoronary gene delivery in mice has been used to increase transduction efficiency in the heart. Although mouse models have been useful, there is a major limitation in the form of ventricular dysfunction arising in global or cardiomyocyte-specific overexpression and deletion models.¹¹⁷ Furthermore, translating findings in mice to human is limited for several reasons. Firstly, the APD in mice is much shorter than that in humans and the ionic currents underlying short APD are also different. Secondly, differences in intracellular Ca²⁺-handling in mice affect the mechanisms and propensity for triggered beats. Last, the tiny size of the mouse atrium influences susceptibility to initiate a re-entrant circuit.⁷⁵

6.2 | Gene delivery in large AF animal models and translational studies

Generating AF models in large animal species is challenging due to their size, age and expense. Initiation of AF can be difficult and time consuming, often taking several weeks of rapid atrial pacing. Contrary to mice models, interpretation of data in large animal models is more translatable to human AF, particularly in the context of efficacy of novel pharmacotherapy and ablation therapy. Clinically applicable catheter-based cardiac-targeted gene delivery modes including antegrade intracoronary perfusion, recirculation perfusion and retrograde intravenous perfusion have been successfully used in either phase 1 or 2 clinical trials and preclinical studies. However, it should be noted that endothelial dysfunction, atherosclerosis and the occlusion of coronary arteries may limit transduction efficiency, subsequently washing out a substantial amount of vector dosage.

7 | FUTURE GENE THERAPEUTIC SOLUTIONS

7.1 | Targeted delivery of gene therapy using activation mapping and imaging

Since the description of the role of structural remodeling in AF, there has been increasing research on atrial fibrosis in the pathophysiology of AF.¹¹⁹ Imaging methods have been developed to detect, localize, and quantify atrial fibrosis, which correlated with outcomes such as stroke and recurrence of AF.^{120,121} In vivo activation mapping methods may allow targeted therapy of AF-specific mechanisms and may detect atrial substrates and mechanisms initiating and/or maintaining AF.^{122,123} Advances in percutaneous catheter-based techniques with fluoroscopic and electroanatomic guidance should allow a less invasive, transendocardial gene delivery. Importantly, electroanatomical mapping may be useful to allow clear delineation of the region of interest and targeted deployment of the therapeutic product.¹²⁴ This could be applicable not only in the ventricle (i.e., in the presence of chronic ischemic heart disease and subacute myocardial infarction) but also in the atria (i.e., targeting focal structural or electrical remodeling).

8 | CONCLUSION

This review article summarizes current gene therapy strategies for the treatment of AF. Further development of gene therapy for this condition is encouraged by the limited efficacy

of pharmacological and catheter-based therapies for AF. While AF remains a complex and heterogeneous clinical entity, gene therapy targeting multiple signaling pathways show very promising results in preclinical models. Improved longevity of vectors and expansion of targeting and delivery of vectors may lead to the development of effective and long-lasting treatment for AF.

ACKNOWLEDGEMENTS

RA: R01 HL093490; R01 HL140061; AHA Strategically Focused Research Networks AF Center grant; NIH Center for Accelerated Innovations at Cleveland Clinic (NCAI-CC).

Funding information

AHA Strategically Focused Research Networks AF Center grant; NIH Center for Accelerated Innovations at Cleveland Clinic (NCAI-CC); National Heart, Lung, and Blood Institute, Grant/Award Numbers: RA: R01 HL093490, R01 HL140061

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are openly available in [repository name e.g., “figshare”] at [doi], reference number [reference number].

Abbreviations:

AAV9	adeno-associated virus serotype 9
ACh	acetylcholine
AF	atrial fibrillation
APD	action potential duration
CaM	calmodulin
CPVT	catecholaminergic polymorphic ventricular tachycardia
CREM	cAMP response element
Cx	connexin
ERP	effective refractory period
GFP	green fluorescent protein
I_{CaL}	L-type Ca^{2+} current
I_{K1}	inward-rectifier K^+ current
I_{KACH}	acetylcholine-dependent K^+ current
I_{KH}	constitutively active form of I_{KACH}
Nab	neutralizing antibody
NLRP3	NACHT, LRR and PYD domains-containing protein 3

NOX2	NADPH oxidase 2
RAP	rapid atrial pacing
ROS	reactive oxygen species
shRNA	short hairpin RNA
TASK-1	Tandem of P domains in a weak inward rectifying K ⁺ channel–related acid-sensitive K ⁺ channel-1

REFERENCES

- Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. *Am J Cardiol*. 2013;112(8):1142–1147. [PubMed: 23831166]
- Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. *Circ Arrhythm Electrophysiol*. 2008;1(1):62–73. [PubMed: 19808395]
- Benjamin EJ, Chen PS, Bild DE, et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. *Circulation*. 2009;119(4):606–618. [PubMed: 19188521]
- Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. *Lancet*. 2010;375(9721):1212–1223. [PubMed: 20334907]
- Piccini JP, Fauchier L. Rhythm control in atrial fibrillation. *Lancet*. 2016;388(10046):829–840. [PubMed: 27560278]
- Grieger JC, Samulski RJ. Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. *J Virol*. 2005;79(15):9933–9944. [PubMed: 16014954]
- Nierman WC, Feldblyum TV. Genomic Library. In: Brenner S, ed. *Encyclopedia of Genetics*. Elsevier; 2001:865–872.
- Schmeer M, Buchholz T, Schlee M. Plasmid DNA manufacturing for indirect and direct clinical applications. *Hum Gene Ther*. 2017;28(10):856–861. [PubMed: 28826233]
- Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. *Curr Opin Immunol*. 2011;23(3):421–429. [PubMed: 21530212]
- Su CH, Wu YJ, Wang HH, Yeh HI. Nonviral gene therapy targeting cardiovascular system. *Am J Physiol Heart Circ Physiol*. 2012;303(6):H629–H638. [PubMed: 22821991]
- Kaestner L, Scholz A, Lipp P. Conceptual and technical aspects of transfection and gene delivery. *Bioorg Med Chem Lett*. 2015;25(6):1171–1176. [PubMed: 25677659]
- Lin H, Parmacek MS, Morle G, Bolling S, Leiden JM. Expression of recombinant genes in myocardium in vivo after direct injection of DNA. *Circulation*. 1990;82(6):2217–2221. [PubMed: 2173647]
- Kunamalla A, Ng J, Parini V, et al. Constitutive expression of a dominant-negative TGF-beta type II receptor in the posterior left atrium leads to beneficial remodeling of atrial fibrillation substrate. *Circ Res*. 2016;119(1):69–82. [PubMed: 27217399]
- Huang M, Chan DA, Jia F, et al. Short hairpin RNA interference therapy for ischemic heart disease. *Circulation*. 2008;118(14 Suppl):S226–S233. [PubMed: 18824759]
- Levi B, Hyun JS, Nelson ER, et al. Nonintegrating knockdown and customized scaffold design enhances human adipose-derived stem cells in skeletal repair. *Stem Cells*. 2011;29(12):2018–2029. [PubMed: 21997852]
- Eefting D, Grimbergen JM, de Vries MR, et al. Prolonged in vivo gene silencing by electroporation-mediated plasmid delivery of small interfering RNA. *Hum Gene Ther*. 2007;18(9):861–869. [PubMed: 17850190]
- Escoffre JM, Debin A, Reynes JP, et al. Long-lasting in vivo gene silencing by electrotransfer of shRNA expressing plasmid. *Technol Cancer Res Treat*. 2008;7(2):109–116. [PubMed: 18345699]

18. Yew NS, Przybylska M, Ziegler RJ, Liu D, Cheng SH. High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter. *Mol Ther.* 2001;4(1):75–82. [PubMed: 11472109]
19. Turnbull IC, Eltoukhy AA, Fish KM, et al. Myocardial delivery of lipidoid nanoparticle carrying modRNA induces rapid and transient expression. *Mol Ther.* 2016;24(1):66–75. [PubMed: 26471463]
20. Zylberberg C, Gaskill K, Pasley S, Matosevic S. Engineering liposomal nanoparticles for targeted gene therapy. *Gene Therapy.* 2017;24(8):441–452. [PubMed: 28504657]
21. Friedman AD, Claypool SE, Liu R. The smart targeting of nanoparticles. *Curr Pharm Des.* 2013;19(35):6315–6329. [PubMed: 23470005]
22. Jirikowski GF, Sanna PP, Maciejewski-Lenoir D, Bloom FE. Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. *Science.* 1992;255(5047):996–998. [PubMed: 1546298]
23. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. *Science.* 1990;247(4949 Pt 1):1465–1468. [PubMed: 1690918]
24. McIvor RS. Therapeutic delivery of mRNA: the medium is the message. *Mol Ther.* 2011;19(5):822–823. [PubMed: 21532608]
25. Kariko K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. *Immunity.* 2005;23(2):165–175. [PubMed: 16111635]
26. Kaur K, Zangi L. Modified mRNA as a therapeutic tool for the heart. *Cardiovasc Drugs Ther.* 2020;34(6):871–880. [PubMed: 32822006]
27. Hadas Y, Vincek AS, Youssef E, et al. Altering sphingolipid metabolism attenuates cell death and inflammatory response after myocardial infarction. *Circulation.* 2020;141(11):916–930. [PubMed: 31992066]
28. Sultana N, Magadam A, Hadas Y, et al. Optimizing cardiac delivery of modified mRNA. *Mol Ther.* 2017;25(6):1306–1315. [PubMed: 28389322]
29. Zangi L, Oliveira MS, Ye LY, et al. Insulin-like growth factor 1 receptor-dependent pathway drives epicardial adipose tissue formation after myocardial injury. *Circulation.* 2017;135(1):59–72. [PubMed: 27803039]
30. Zangi L, Lui KO, von Gise A, et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. *Nat Biotechnol.* 2013;31(10):898–907. [PubMed: 24013197]
31. Hinderer C, Katz N, Buza EL, et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. *Hum Gene Ther.* 2018;29(3):285–298. [PubMed: 29378426]
32. Carter BJ. Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective. *Mol Ther.* 2004;10(6):981–989. [PubMed: 15564130]
33. Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. *Science.* 1965;149(3685):754–756. [PubMed: 14325163]
34. Tilemann L, Ishikawa K, Weber T, Hajjar RJ. Gene therapy for heart failure. *Circ Res.* 2012;110(5):777–793. [PubMed: 22383712]
35. Kieserman JM, Myers VD, Dubey P, Cheung JY, Feldman AM. Current landscape of heart failure gene therapy. *J Am Heart Assoc.* 2019;8:10.
36. Liu Z, Donahue JK. The use of gene therapy for ablation of atrial fibrillation. *Arrhythm Electrophysiol Rev.* 2014;3(3):139–144. [PubMed: 26835081]
37. Rotundo IL, Lancioni A, Savarese M, et al. Use of a lower dosage liver-detargeted AAV vector to prevent hamster muscular dystrophy. *Hum Gene Ther.* 2013;24(4):424–430. [PubMed: 23427808]
38. Yang L, Jiang J, Drouin LM, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. *Proc Natl Acad Sci USA.* 2009;106(10):3946–3951. [PubMed: 19234115]
39. Yang L, Jiang J, Drouin LM, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. *Proc Natl Acad Sci.* 2009;106(10):3946–3951. [PubMed: 19234115]

40. Ni L, Scott L Jr, Campbell HM, et al. Atrial-specific gene delivery using an adeno-associated viral vector. *Circ Res*. 2019;124(2):256–262. [PubMed: 30582449]
41. Goswami R, Subramanian G, Silayeva L, et al. Gene therapy leaves a vicious cycle. *Front Oncol*. 2019;9:9. [PubMed: 30723704]
42. Rincon MY, Vandendriessche T, Chuah MK. Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation. *Cardiovasc Res*. 2015;108(1):4–20. [PubMed: 26239654]
43. Pleger ST, Shan C, Ksienzyk J, et al. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. *Sci Transl Med*. 2011;3(92):92ra64.
44. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. *J Virol*. 1996;70(5):3227–3234. [PubMed: 8627803]
45. Greener I, Donahue JK. Gene therapy strategies for cardiac electrical dysfunction. *J Mol Cell Cardiol*. 2011;50(5):759–765. [PubMed: 20696170]
46. Hajjar RJ. Potential of gene therapy as a treatment for heart failure. *J Clin Invest*. 2013;123(1):53–61. [PubMed: 23281410]
47. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. *Mol Genet Metab*. 2003;80(1-2):148–158. [PubMed: 14567964]
48. Williams P, Ranjzad P, Kakar S, Kingston P. Development of viral vectors for use in cardiovascular gene therapy. *Viruses*. 2010;2(2):334–371. [PubMed: 21994642]
49. Milone MC, O’Doherty U. Clinical use of lentiviral vectors. *Leukemia*. 2018;32(7):1529–1541. [PubMed: 29654266]
50. Di Pasquale E, Latronico MVG, Jotti GS, Condorelli G. Lentiviral vectors and cardiovascular diseases: a genetic tool for manipulating cardiomyocyte differentiation and function. *Gene Therapy*. 2012;19(6):642–648. [PubMed: 22378345]
51. Bonci D, Cittadini A, Latronico MV, et al. ‘Advanced’ generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. *Gene Ther*. 2003;10(8):630–636. [PubMed: 12692591]
52. Kumar M, Keller B, Makalou N, Sutton RE. Systematic determination of the packaging limit of lentiviral vectors. *Hum Gene Ther*. 2001;12(15):1893–1905. [PubMed: 11589831]
53. Cockrell AS, Kafri T. Gene delivery by lentivirus vectors. *Mol Biotechnol*. 2007;36(3):184–204. [PubMed: 17873406]
54. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. *Mol Gen Metab*. 2003;80(1-2):148–158.
55. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. *J Infect Dis*. 2009;199(3):381–390. [PubMed: 19133809]
56. Ronzitti G, Gross D-A, Mingozzi F. Human immune responses to adeno-associated virus (AAV) vectors. *Front Immunol*. 2020;11:11. [PubMed: 32082309]
57. Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. *Blood*. 2013;122(1):23–36. [PubMed: 23596044]
58. Shirley JL, De Jong YP, Terhorst C, Herzog RW. Immune responses to viral gene therapy vectors. *Mol Ther*. 2020;28(3):709–722. [PubMed: 31968213]
59. Yla-Herttuala S. Gene therapy for heart failure: back to the bench. *Mol Ther*. 2015;23(10):1551–1552. [PubMed: 26442799]
60. Greenberg B, Butler J, Felker GM, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPIID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. *Lancet*. 2016;387(10024):1178–1186. [PubMed: 26803443]
61. Zincarelli C, Soltys S, Rengo G, Koch WJ, Rabinowitz JE. Comparative cardiac gene delivery of adeno-associated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart. *Clin Transl Sci*. 2010;3(3):81–89. [PubMed: 20590676]

62. Boekstegers P, Von Degenfeld G, Giehl W, et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. *Gene Therapy*. 2000;7(3):232–240. [PubMed: 10694800]
63. Hatori N, Sjöquist P-O, Regårdh C, Rydén L. Pharmacokinetic analysis of coronary sinus retroinfusion in pigs. *Cardiovasc Drugs Ther*. 1991;5(6):1005–1010. [PubMed: 1801888]
64. Karagueuzian HS, Ohta M, Drury JK, et al. Coronary venous retroinfusion of procainamide: a new approach for the management of spontaneous and inducible sustained ventricular tachycardia during myocardial infarction. *J Am Coll Cardiol*. 1986;7(3):551–563. [PubMed: 3950235]
65. Kikuchi K, McDonald AD, Sasano T, Donahue JK. Targeted modification of atrial electrophysiology by homogeneous transmural atrial gene transfer. *Circulation*. 2005;111(3):264–270. [PubMed: 15642761]
66. Donahue JK, McDonald AD, Kikuchi K. Inventors; The Johns Hopkins University, assignee. Gene delivery to organs. 2004
67. Luderitz B Historical perspectives of cardiac electrophysiology. *Hellenic J Cardiol*. 2009;50(1):3–16. [PubMed: 19196616]
68. Ishikawa K, Weber T, Hajjar RJ. Human cardiac gene therapy. *Circ Res*. 2018;123(5):601–613. [PubMed: 30355138]
69. Katz MG, Fargnoli AS, Pritchette LA, Bridges CR. Gene delivery technologies for cardiac applications. *Gene Ther*. 2012;19(6):659–669. [PubMed: 22418063]
70. Katz MG, Swain JD, White JD, Low D, Stedman H, Bridges CR. Cardiac gene therapy: optimization of gene delivery techniques in vivo. *Hum Gene Ther*. 2010;21(4):371–380. [PubMed: 19947886]
71. Marshall WG Jr, Jr., Boone BA, Burgos JD, et al. Electroporation-mediated delivery of a naked DNA plasmid expressing VEGF to the porcine heart enhances protein expression. *Gene Ther*. 2010;17(3):419–423. [PubMed: 19956270]
72. Mali B, Jarm T, Corovic S, et al. The effect of electroporation pulses on functioning of the heart. *Med Biol Eng Comput*. 2008;46(8):745–757. [PubMed: 18415132]
73. van Es R, Konings MK, Du Pré BC, et al. High-frequency irreversible electroporation for cardiac ablation using an asymmetrical waveform. *Biomed Eng Online*. 2019;18(1):75. [PubMed: 31221146]
74. Donahue JK. Current state of the art for cardiac arrhythmia gene therapy. *Pharmacol Ther*. 2017;176:60–65. [PubMed: 28642118]
75. Hucker WJ, Hanley A, Ellinor PT. Improving atrial fibrillation therapy: is there a gene for that? *J Am Coll Cardiol*. 2017;69(16):2088–2095. [PubMed: 28427583]
76. Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. *J Am Coll Cardiol*. 2014;63(22):2335–2345. [PubMed: 24613319]
77. Perlstein I, Burton DY, Ryan K, et al. Posttranslational control of a cardiac ion channel transgene in vivo: clarithromycin-hMiRP1-Q9E interactions. *Hum Gene Ther*. 2005;16(7):906–910. [PubMed: 16000071]
78. Amit G, Kikuchi K, Greener ID, Yang L, Novack V, Donahue JK. Selective molecular potassium channel blockade prevents atrial fibrillation. *Circulation*. 2010;121(21):2263–2270. [PubMed: 20479154]
79. Soucek R, Thomas D, Kelemen K, et al. Genetic suppression of atrial fibrillation using a dominant-negative ether-a-go-go-related gene mutant. *Heart Rhythm*. 2012;9(2):265–272. [PubMed: 21907172]
80. Schmidt C, Wiedmann F, Beyersdorf C, et al. Genetic ablation of TASK-1 (Tandem of P domains in a weak inward rectifying K(+) channel-related acid-sensitive K(+) channel-1) (K2P3.1) K(+) channels suppresses atrial fibrillation and prevents electrical remodeling. *Circ Arrhythm Electrophysiol*. 2019;12(9):e007465. [PubMed: 31514528]
81. Voigt N, Heijman J, Wang Q, et al. Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. *Circulation*. 2014;129(2):145–156. [PubMed: 24249718]

82. Voigt N, Li N, Wang Q, et al. Enhanced sarcoplasmic reticulum Ca²⁺ leak and increased Na⁺-Ca²⁺ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. *Circulation*. 2012;125(17):2059–2070. [PubMed: 22456474]
83. Li N, Chiang DY, Wang S, et al. Ryanodine receptor-mediated calcium leak drives progressive development of an atrial fibrillation substrate in a transgenic mouse model. *Circulation*. 2014;129(12):1276–1285. [PubMed: 24398018]
84. Li N, Wang T, Wang W, et al. Inhibition of CaMKII phosphorylation of RyR2 prevents induction of atrial fibrillation in FKBP12.6 knockout mice. *Circ Res*. 2012;110(3):465–470. [PubMed: 22158709]
85. Brunello L, Slabaugh JL, Radwanski PB, et al. Decreased RyR2 refractoriness determines myocardial synchronization of aberrant Ca²⁺ release in a genetic model of arrhythmia. *Proc Natl Acad Sci USA*. 2013;110(25):10312–10317. [PubMed: 23733959]
86. Loaiza R, Benkusky NA, Powers PP, et al. Heterogeneity of ryanodine receptor dysfunction in a mouse model of catecholaminergic polymorphic ventricular tachycardia. *Circ Res*. 2013;112(2):298–308. [PubMed: 23152493]
87. Liu B, Walton SD, Ho HT, et al. Gene transfer of engineered calmodulin alleviates ventricular arrhythmias in a calsequestrin-associated mouse model of catecholaminergic polymorphic ventricular tachycardia. *J Am Heart Assoc*. 2018;7(10):e008155. [PubMed: 29720499]
88. Arora R, Ulphani JS, Villuendas R, et al. Neural substrate for atrial fibrillation: implications for targeted parasympathetic blockade in the posterior left atrium. *Am J Physiol Heart Circ Physiol*. 2008; 294(1):H134–H144. [PubMed: 17982017]
89. Chen PS, Chen LS, Fishbein MC, Lin SF, Nattel S. Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. *Circ Res*. 2014;114(9):1500–1515. [PubMed: 24763467]
90. Nergardh AK, Rosenqvist M, Nordlander R, Frick M. Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double-blind placebo-controlled study. *Eur Heart J*. 2007;28(11):1351–1357. [PubMed: 17329409]
91. Machida T, Hashimoto N, Kuwahara I, et al. Effects of a highly selective acetylcholine-activated K⁺ channel blocker on experimental atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2011;4(1):94–102. [PubMed: 21156770]
92. Donahue JK, Heldman AW, Fraser H, et al. Focal modification of electrical conduction in the heart by viral gene transfer. *Nat Med*. 2000;6(12):1395–1398. [PubMed: 11100126]
93. Murata M, Cingolani E, McDonald AD, Donahue JK, Marban E. Creation of a genetic calcium channel blocker by targeted gem gene transfer in the heart. *Circ Res*. 2004;95(4):398–405. [PubMed: 15242970]
94. Lugenbiel P, Thomas D, Kelemen K, et al. Genetic suppression of Galphas protein provides rate control in atrial fibrillation. *Basic Res Cardiol*. 2012;107(3):265. [PubMed: 22457123]
95. Aistrup GL, Cokic I, Ng J, et al. Targeted nonviral gene-based inhibition of Galpha(i/o)-mediated vagal signaling in the posterior left atrium decreases vagal-induced atrial fibrillation. *Heart Rhythm*. 2011;8(11):1722–1729. [PubMed: 21689540]
96. Carmeliet E Cardiac ionic currents and acute ischemia: from channels to arrhythmias. *Physiol Rev*. 1999;79(3):917–1017. [PubMed: 10390520]
97. Tuomi JM, Tyml K, Jones DL. Atrial tachycardia/fibrillation in the connexin 43 G60S mutant (Oculodentodigital dysplasia) mouse. *Am J Physiol Heart Circ Physiol*. 2011;300(4):H1402–H1411. [PubMed: 21239638]
98. Chaldoupi SM, Loh P, Hauer RN, de Bakker JM, van Rijen HV. The role of connexin40 in atrial fibrillation. *Cardiovasc Res*. 2009;84(1):15–23. [PubMed: 19535379]
99. Igarashi T, Finet JE, Takeuchi A, et al. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. *Circulation*. 2012;125(2):216–225. [PubMed: 22158756]
100. Bikou O, Thomas D, Trappe K, et al. Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. *Cardiovasc Res*. 2011;92(2):218–225. [PubMed: 21799069]
101. Doetschman T, Barnett JV, Runyan RB, et al. Transforming growth factor beta signaling in adult cardiovascular diseases and repair. *Cell Tissue Res*. 2012;347(1):203–223. [PubMed: 21953136]

102. Nattel S, Heijman J, Zhou L, Dobrev D. Molecular basis of atrial fibrillation pathophysiology and therapy: a translational perspective. *Circ Res*. 2020;127(1):51–72. [PubMed: 32717172]
103. Sirish P, Li N, Timofeyev V, et al. Molecular mechanisms and new treatment paradigm for atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2016;9(5):e003721. [PubMed: 27162031]
104. Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. *Nat Rev Cardiol*. 2015;12(4):230–243. [PubMed: 25622848]
105. Yao C, Veleva T, Scott L Jr, et al. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation. *Circulation*. 2018;138(20):2227–2242. [PubMed: 29802206]
106. Sovari AA. Cellular and molecular mechanisms of arrhythmia by oxidative stress. *Cardiol Res Pract*. 2016;2016:9656078. [PubMed: 26981310]
107. Dudley SC Jr, Jr., Hoch NE, McCann LA, et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. *Circulation*. 2005;112(9):1266–1273. [PubMed: 16129811]
108. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. *Trends Pharmacol Sci*. 2003;24(9):471–478. [PubMed: 12967772]
109. Cai H. Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences. *Cardiovasc Res*. 2005;68(1):26–36. [PubMed: 16009356]
110. Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. *JAMA*. 2008;300(18):2123–2133. [PubMed: 18997197]
111. Thiele H, Hildebrand L, Schirdewahn C, et al. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate Percutaneous Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. *J Am Coll Cardiol*. 2010;55(20):2201–2209. [PubMed: 20466200]
112. Forman HJ, Davies KJ, Ursini F. How do nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavenging in vivo. *Free Radic Biol Med*. 2014;66:24–35. [PubMed: 23747930]
113. Yoo S, Pfenniger A, Hoffman J, et al. Attenuation of oxidative injury with targeted expression of NADPH oxidase 2 short hairpin RNA prevents onset and maintenance of electrical remodeling in the canine atrium: a novel gene therapy approach to atrial fibrillation. *Circulation*. 2020;142(13):1261–1278. [PubMed: 32686471]
114. Li Y, Gong ZH, Sheng L, et al. Anti-apoptotic effects of a calpain inhibitor on cardiomyocytes in a canine rapid atrial fibrillation model. *Cardiovasc Drugs Ther*. 2009;23(5):361–368. [PubMed: 19882242]
115. Trappe K, Thomas D, Bikou O, et al. Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study. *Eur Heart J*. 2013;34(2):147–157. [PubMed: 21785105]
116. Zhang Y, Zheng S, Geng Y, et al. MicroRNA profiling of atrial fibrillation in canines: miR-206 modulates intrinsic cardiac autonomic nerve remodeling by regulating SOD1. *PLoS One*. 2015;10(3):e0122674. [PubMed: 25816284]
117. Dobrev D, Wehrens XHT. Mouse models of cardiac arrhythmias. *Circ Res*. 2018;123(3):332–334. [PubMed: 30026380]
118. Fang H, Lai NC, Gao MH, et al. Comparison of adeno-associated virus serotypes and delivery methods for cardiac gene transfer. *Hum Gene Ther Methods*. 2012;23(4):234–241. [PubMed: 22966786]
119. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs. *Circulation*. 1999;100(1):87–95. [PubMed: 10393686]
120. Daccarett M, Badger TJ, Akoum N, et al. Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. *J Am Coll Cardiol*. 2011;57(7):831–838. [PubMed: 21310320]
121. Han FT, Akoum N, Marrouche N. Value of magnetic resonance imaging in guiding atrial fibrillation management. *Can J Cardiol*. 2013;29(10):1194–1202. [PubMed: 24074971]

122. Cuculich PS, Wang Y, Lindsay BD, et al. Noninvasive characterization of epicardial activation in humans with diverse atrial fibrillation patterns. *Circulation*. 2010;122(14):1364–1372. [PubMed: 20855661]
123. Narayan SM, Krummen DE, Shivkumar K, Clopton P, Rappel WJ, Miller JM. Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) trial. *J Am Coll Cardiol*. 2012;60(7):628–636. [PubMed: 22818076]
124. Banovic M, Ostojic MC, Bartunek J, Nedeljkovic M, Beleslin B, Terzic A. Brachial approach to NOGA-guided procedures: electromechanical mapping and transendocardial stem-cell injections. *Tex Heart Inst J*. 2011;38(2):179–182. [PubMed: 21494532]